Special Offers
100% Performance Guaranteed
Key Specifications Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| H, R, Chp | IH(P), FC, NEUT, ICC | M | Purified | Monoclonal Antibody |
| Description | |
|---|---|
| Catalogue Number | MABC980 |
| Description | Anti-PD-L1 Antibody, clone 29E.2A3.C6, Azide Free |
| Alternate Names |
|
| Background Information | Programmed cell death 1 ligand 1 (UniProt Q9NZQ7; also known as B7-H1, B7 homolog 1, CD274, PD-L1, PDCD1 ligand 1, Programmed death ligand 1) is encoded by the CD274 (also known as B7H1, PDCD1L1, PDCD1LG1, PDL1) gene (Gene ID 29126) in human. PD-1 and PD-1 ligands 1&2 (PD-L1 and PD-L2) are B7:CD28 family members that regulate T cell activation and peripheral tolerance. When engaged together with the TCR, the interaction of PD-1 with its ligands delivers an inhibitory signal to T cell proliferation and cytokine production. While PD-L1 is broadly expressed in hematopoietic and nonhematopoietic cells, PD-L2 expression is highly restricted to antigen presenting cells (APCs), including dendritic cells (DCs) and macrophages. The PD-1 pathway plays a key role in the progressive loss of effector T cell responses during chronic HIV infection. Under some conditions, blockade of this pathway is able to restore many T cell functions. PD-L1 is initially produced with signal peptide (a.a. 1-18) sequence, the removal of which yields the mature protien with a large extracellular (a.a. 19-238) region that contains an Ig-like V-type domain (a.a. 19-127) and an Ig-like C2-type domain (a.a. 133-225), followed by a transmembrane domain (a.a. 239-259) and a cytoplasmic tail (a.a. 260-290). |
| Product Information | |
|---|---|
| Format | Purified |
| Presentation | Purified mouse monoclonal IgG2bκ antibody in PBS without preservatives. |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Anti-PD-L1 Antibody, clone 29E.2A3.C6, Azide Free is an antibody against PD-L1 for use in Immunohistochemistry (Paraffin), Flow Cytometry, Neutralizing, Immunocytochemistry. |
| Key Applications |
|
| Application Notes | Immunohistochemistry Analysis: An 1:50 dilution of this antibody from a representative lot detected PD-L1 in human kidney and rat colon tissue. Flow Cytometry Analysis: 0.1 µg of this antibody from a representative lot detected PD-L1 in MDA-MB-231 cells. Flow Cytometry Analysis: A representative lot immunostained the surface of 300.19 murine pre-B lymphoma cells transfected with human PD-L1, but not the untransfected cells or cells transfected with human PD-L2 (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266). Flow Cytometry Analysis: A representative lot detected surface PD-L1 expression on human breast cancer cell lines MDA-231, SKBR-3, and MCF-7, but not BT-474 (Latchman, Y., et al. (2001). J. Nat. Immunol.2(3):261-268). Immunohistochemistry Analysis: A representative lot detected PD-L1 expression pattern in frozen fetal (thymus & cardiac tissue) and paraffin-embedded adult (tonsillar germinal center and placenta) human tissue sections (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266). Immunohistochemistry Analysis: A representative lot detected PD-L1 expression in paraffin-embedded human cancer tissue sections, including anaplastic large cell lymphoma, squamous cell carcinoma of the tongue, colon adenocarcinoma, and invasive breast ductal carcinoma (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266). Neutralizing Analysis: A representative lot competed against human PD-1 extracellular domain Ig fusion for the binding of exogenously expressed human PD-L1 on the surface of 300.19 murine pre-B lymphoma cells (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266). Neutralizing Analysis: A representative lot enhanced cytokines production from CD4 T-cells upon HIV Gag peptides stimulation of CD8+-depleted human PBMCs (Porichis, F., et al. (2011). Blood. 118(4):965-974). Neutralizing Analysis: A representative lot restored HCV peptides-induced expansion of CD8+ T cells in cultured intrahepatic lymphocytes from a chimpanzee with 10 years of chronic HCV infection (Fuller, M.J., et al. (2013). Proc. Natl. Acad. Sci. U. S. A. 110(37):15001-15006). Neutralizing Analysis: Dual blockage of both DP-L1 clone 29E.2A3.C6 Fab fragment and DP-L2 by clone 24F.10C12 (Cat. No. MABC969) Fab fragment on PBMC-derived dendric cells (DCs) boosted the enhancing effect on CD4+ T-cell proliferation and cytokine release seen with DP-L2 blockage alone in allogenic cultures with immature DCs (iDC), mature DCs (mDC), and IL-10-treated mDCs (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266). Immunocytochemistry Analysis: A representative lot detected an upregulated PD-L1 immunoreactivity in human CD14+ monocyte-derived macrophages (MDMs) following HIV infection or TLR4/8 stimulation (by LPS or CL097 treatment) by fluorescent immunocytochemistry using paraformaldehyde-fixed MDMs (Rodríguez-García, M., et al. (2011). J. Leukoc. Biol. 89(4) 507–515). |
| Biological Information | |
|---|---|
| Immunogen | Recombinant full-length human PD-L1. |
| Epitope | Extracellular domain. |
| Clone | 29E.2A3.C6 |
| Concentration | Please refer to lot specific datasheet. |
| Host | Mouse |
| Specificity | Clone 29E.2A3.C6 immunostained the surface of 300.19 murine pre-B lymphoma cells transfected with human PD-L1, but not the untransfected cells or cells transfected with human PD-L2 (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266). Reactivity toward spliced isoform 2 (PD-L1II) and isoform 3 has not been determined. |
| Isotype | IgG2bκ |
| Species Reactivity |
|
| Antibody Type | Monoclonal Antibody |
| Entrez Gene Number |
|
| Gene Symbol |
|
| Purification Method | Protein G Purified |
| UniProt Number |
|
| Molecular Weight | 31.02 kDa (isoform 1; PD-L1I), 17.99 kDa (isoform 2; PD-L1II), 18.20 kDa (isoform 3) calculated. |
| Product Usage Statements | |
|---|---|
| Quality Assurance | Evaluated by Immunohistochemistry in human cerebral cortex tissue. Immunohistochemistry Analysis: An 1:50 dilution of this antibody detected PD-L1 in human cerebral cortex tissue. |
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Stable for 1 year at -20°C from date of receipt. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. |
| Packaging Information | |
|---|---|
| Material Size | 100 μg |